SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients ( n = 53) had partial or complete vaccination schemes with CanSino (45%), Sinovac (19%), Pfizer/BioNTech (15%), and AstraZeneca/Oxford (15%). CanSino was administered most frequently in ambulatory patients ( p < 0.01). The control group ( n = 19) received no COVID-19 vaccines. Among SARS-CoV-2 variants detected by whole-genome sequencing, VOC Delta B.1.617.2 predominated in vaccinated ambulatory patients ( p < 0.01) and AY.4 in hospitalized patients ( p = 0.04); VOI Mu B.1.621 was detected in four (7.55%) vaccinated patients. SARS-CoV-2 breakthrough infections in our hospital occurred mostly in patients vaccinated with CanSino due to the higher prevalence of CanSino vaccine administration in our population. These patients developed mild COVID-19 symptoms not requiring hospitalization. The significance of this study lies on the detection of SARS-CoV-2 variants compromising the efficacy of local immunization therapies in Monterrey, Mexico.
【저자키워드】 COVID-19, SARS-CoV-2, Delta, COVID-19 vaccines, Mexico, Surveillance, variant of concern, Latin America, Mu, CanSino, 【초록키워드】 whole-genome sequencing, public health, Efficacy, Vaccine, vaccination, therapy, Hospitalized, Hospitalization, Vaccines, VoC, SARS-COV-2 infection, hospital, SARS-CoV-2 variant, B.1.617.2, Local, hospitalized patients, immunization, SARS-CoV-2 vaccine, Prevalence, COVID-19 vaccines, SARS-CoV-2 variants, inoculation, VOCs, Patient, breakthrough infections, Breakthrough infection, VOIs, patients, AstraZeneca, Sinovac, B.1.621, case-control study, Pfizer/BioNTech, vaccine breakthrough infections, control group, increased risk, ambulatory patients, second dose, first dose, vaccine administration, mild COVID-19 symptoms, Administered, Complete, vaccine breakthrough infection, defined, occurred, was performed, hospitalized patient, ambulatory patient, mild COVID-19 symptom, 【제목키워드】 concern, interest,